How to find an FDA product code for a medical device
Search device names, compare classification definitions, and distinguish a product code from a clearance number or UDI.
Read the guide →Medical-device intelligence
FDA product code NYI: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer. View classification details, related manufacturers, 510(k) clearances, and recall records.
A device which uses a gene expression profile of a breast cancer tumor, from patients stage i or stage ii lymph node negative, with a tumor size of <5.0 cm, to provide a risk assessment for distant recurrence of breast cancer. The result is indicated for use only as a prognostic marker by physicians along with a number of other factors to assess the risk of recurrence of breast cancer.Explore immunology records →
9 clearance records and 1 recall records in the covered releases, across 5 source company names and 1 product codes. Dated history runs from Jun 22, 2007 to Sep 8, 2022.
| Month | 510(k) decisions | Recall initiations |
|---|---|---|
| October 2025 | 0 | 0 |
| November 2025 | 0 | 0 |
| December 2025 | 0 | 0 |
| January 2026 | 0 | 0 |
| February 2026 | 0 | 0 |
| March 2026 | 0 | 0 |
| April 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| June 2026 | 0 | 0 |
| July 2026 | 0 | 0 |
| August 2026 | 0 | 0 |
| September 2026 | 0 | 0 |
| October 2026 | 0 | 0 |
| Code and FDA device name | Clearances | Recalls |
|---|---|---|
| NYI · Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer | 9 | 1 |
| Device / record | Company in FDA record | Source | Source date |
|---|---|---|---|
| MammaPrint FFPE NGS KitK210973 · NYI | Agendia, Inc. | 510(k) | Sep 8, 2022FDA decision date |
| MammaPrintK201902 · NYI | Agendia, Inc. | 510(k) | Nov 5, 2020FDA decision date |
| MAMMAPRINT FFPEK141142 · NYI | Agendia | 510(k) | Jan 23, 2015FDA decision date |
| PROSIGNA BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAYK141771 · NYI | Nanostring Technologies, Inc. | 510(k) | Nov 7, 2014FDA decision date |
| PROSIGNA(TM) BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAYK130010 · NYI | Nanostring Technologies | 510(k) | Sep 6, 2013FDA decision date |
| MAMMAPRINTK101454 · NYI | Agendia | 510(k) | Jan 28, 2011FDA decision date |
| Agendia MammaPrint, Catalog Numbers MP01, MP US version 03Z-1321-2010 · NYI | Agendia Inc | Recall | Apr 12, 2010FDA classification date |
| MODIFICATION TO MAMMAPRINTK081092 · NYI | Agendia | 510(k) | Dec 11, 2009FDA decision date |
| MODIFICATION TO MAMMAPRINTK080252 · NYI | Agendia BV | 510(k) | Jul 21, 2008FDA decision date |
| MAMMAPRINTK070675 · NYI | Agendia BV | 510(k) | Jun 22, 2007FDA decision date |
Search device names, compare classification definitions, and distinguish a product code from a clearance number or UDI.
Read the guide →Understand the K number, applicant, decision date, product code, and limits of the public clearance record.
Read the guide →FDA dataset:
Last successful check: Nov 21, 2026
Source classifications may change.
FDA dataset:
Last successful check: Nov 21, 2026
FDA publishes this dataset monthly.
FDA dataset:
Last successful check: Nov 21, 2026
FDA publishes this dataset weekly.
Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.